Samsung Biologics to launch $1.8 billion all cash bid for PolyPeptide
20/07/2026 24:09
Samsung Biologics to launch $1.8 billion all cash bid for PolyPeptide July 20 (Reuters) - Drugmaker Samsung BioLogics 207940.KS will launch an offer to buy all shares of Swiss contract drugmaker PolyPeptide PPGN.S for 44.31 Swiss francs ($54.81) per share, giving the firm an implied equity value of 1.46 billion Swiss francs ($1.81 billion), the companies said.
($1 = 0.8084 Swiss francs)
(Reporting by Mihika Sharma in Bengaluru; Editing by Christian Schmollinger)
Recent news on PolyPeptide AG
See all newsBrief: Polypeptide Group Definitive Interim Result Of The Public Tender Offer Of Samsung Biologics
Brief: Polypeptide Group Provisional Interim Result Of The Public Tender Offer Of Samsung Biologics Co
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Samsung Biologics to launch takeover bid for PolyPeptide in September (updated)